Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03601286

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

Phase I/II Study of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan

Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust

Conditions Severe Combined Immunodeficiency, X-Linked

Interventions Lentiviral vector transduced CD34+ cells

Updated 8 times since 2018 Last updated: Oct 11, 2023 Started: Dec 21, 2018 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03601286, this PHASE1 trial focuses on Severe Combined Immunodeficiency, X-Linked and remains actively recruiting participants. Sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2022 — Nov 2023 [monthly]

Recruiting PHASE1
Mar 2021 — Apr 2022 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE1
May 2019 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2018 — May 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Great Ormond Street Hospital for Children NHS Foundation Trust

Data source: Great Ormond Street Hospital for Children NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom